Please assess the completion status of the following clinical trial:

Trial Title: Coadministration of Measles-rubella and Rotavirus Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Child 9 months of age eligible for measles-rubella vaccination~* documented evidence of a primary rotavirus vaccine series with first dose between 6 and 10 weeks of age and second dose at least 4 weeks after first dose~* healthy infants free of chronic or serious medical condition as determined by history and physical examination at time of study enrollment~* parents/guardians of each participant are able to understand and follow study procedures and agree to participate in study by providing signed informed consent~Exclusion Criteria:~* hypersensitivity to any component of measles-rubella or Rotarix vaccine which would preclude administration of the vaccine~* history of intussusception, intestinal malformations, or abdominal surgery~* known history of measles and/or rubella disease~* history of previous receipt of measles and/or rubella vaccine~* use of any immunosuppressive drugs or immunoglobulin and/or blood products since birth or anticipated during study period~* current enrolment in any other intervention trial or use of any investigational drug or vaccine throughout the study period~* any participant who reports planning to leave the study area before the completion of the study~* acute diarrhea (defined as ≥3 loose stools within a 24-hour period) or vomiting (defined as projectile vomiting or any vomiting at the discretion of the clinician) at the time of enrollment or within the last 24 hours~* acute febrile illness (defined as a temperature of ≥38°C) at the time of enrollment.

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 11 Months
- Healthy Volunteers: t

Study Arms:
- measles-rubella and rotavirus vaccines (Type: EXPERIMENTAL): receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine and one 1.0 ml dose of oral Rotarix vaccine at 9 months of age
- measles-rubella vaccine (Type: ACTIVE_COMPARATOR): receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine at 9 months of age

Based on this trial design, predict the completion outcome and termination type (if applicable).